Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Feb / Fungal (Library) Growth
Discovery & Development Drug Discovery Research News

Fungal (Library) Growth

Time to mine the biologically active compounds of fungi

By Maryam Mahdi 02/03/2020 0 min read Quick Read (pre 2022)

Share

Thousands of biologically active secondary metabolites derived from different types of fungi have been analyzed and assigned to a library in a joint effort between the Hubrecht Institute, the Westerdijk Fungal Biodiversity Institute and Utrecht University in the Netherlands.

“An aging global population and the growing issue of drug resistance means that we need better and newer drugs, but the number of chemically distinct compounds that are being used in prescription drugs is limited. In addition, the active compounds in these drugs are often chemically related, relying on similar mechanisms to function,” explains research leader, Jeroen den Hertog from the Hubrecht Institute. “Fungi are known to produce pharmaceutically relevant compounds. And despite there being an estimated two million species of fungi, only a small fraction has been analyzed for their expression of biologically active compounds to date.”

The fungal kingdom has remained relatively unexplored in part because access to pure and uncontaminated fungi is limited, making it difficult to assess their bioactive properties. And that’s why Den Hertog and his team were given access to the Westerdijk Institute’s collection of live fungi strains. Using the strains as a starting point, the team produced 1526 filtrates that had biological activity. Among the discoveries, the team found that Resinicium furfuraceum produced the cholesterol lowering drug lovastatin – the first time this fungus has been shown to produce the drug.

The team is also investigating fungi that induce developmental defects in zebrafish, as well as how fungi could help produce new antibiotics. “Using the library that we have generated, we can now screen for the biological activity of fungi using a variety of bioassays,” Den Hertog says. “Further to our initial investigation, we have screened compounds for their antimicrobial activity and found hundreds of fungi that produce compounds that demonstrate antimicrobial activity against multiresistant, pathogenic strains of bacteria.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Antibiotics: Going With the Flow
Drug Discovery Small Molecules
Antibiotics: Going With the Flow

April 2, 2025

2 min read

How fluid flow through the body can affect the ways in which antibiotics work.

Combatting the Side Effects of Treatments for Parkinson’s
Drug Discovery Small Molecules
Combatting the Side Effects of Treatments for Parkinson’s

April 7, 2025

4 min read

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.